# US 2008/0188520 A1 · Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188520 A1
- Document ID: US20080188520A1
- Status: Published application
- Kind: A1
- Application number: 11/954,400
- Filed: 2007-12-12
- Published: 2008-08-07
- Earliest claimed: 2005-06-22
- Assignees: Sanofi-Aventis
- Inventors: Joachim BRENDEL; Heinrich Christian ENGLERT; Stefan PEUKERT; Klaus WIRTH; Michael WAGNER; Jean-Marie RUXER; Fabienne PILORGE
- Web page: https://patentgrep.com/patent/US20080188520A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/27: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D 211/76: attached in position 2 or 6
- C07D 275/02: not condensed with other rings
- C07D 401/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

## Claims

### Claim 1

A compound of formula I,
in which:
A is C, S or S═O;
n is 0, 1, 2 or 3;
R1 is phenyl, pyridyl, thienyl, naphthyl, quinolinyl, pyrimidinyl or pyrazinyl,
where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 C atoms, OCF3, methylsulfonyl, CF3, alkyl having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;
or
R1 is cycloalkyl having 3, 4, 5, 6 or 7 C atoms;
R2 is phenyl, pyridyl, thienyl, naphthyl, quinolinyl, pyrimidinyl or pyrazinyl,
where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, COOMe, CONH2, alkoxy having 1, 2, 3 or 4 C atoms, OCF3, OH, methylsulfonyl, CF3, alkyl having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;
R3 is CpH2p—R8;
p is 0, 1, 2, 3, 4 or 5;
R8 is CH3, CH2F, CHF2, CF3, cycloalkyl having 3, 4, 5, 6 or 7 C atoms, C≡CH, C≡C—CH3, alkoxy having 1, 2, 3 or 4 C atoms, phenyl or pyridyl,
where phenyl and pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 C atoms, alkoxy having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;
R4 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R5 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R6 and R7
are independently of one another hydrogen, F or alkyl having 1, 2, or 3 C atoms;
and the pharmaceutically acceptable salts and trifluoroacetates thereof.

### Claim 2 (depends on 1)

A compound of formula I as claimed in claim 1, in which:
A is C, S or S═O;
n is 0, 1, 2 or 3;
R1 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or 4-pyridazinyl,
where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 C atoms, OCF3, methylsulfonyl, CF3, alkyl having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;
or
R1 is cyclohexyl;
R2 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or 4-pyridazinyl,
where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, COOMe, CONH2, alkoxy having 1, 2, 3 or 4 C atoms, OCF3, OH, methylsulfonyl, CF3, alkyl having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;
R3 is CpH2p—R8;
p is 0, 1, 2, 3, 4 or 5;
R8 is CH3, CH2F, CHF2, CF3, cycloalkyl having 3, 4, 5, 6 or 7 C atoms, C≡CH, C≡C—CH3, alkoxy having 1, 2, 3 or 4 C atoms, phenyl or 2-pyridyl,
where phenyl and 2-pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 C atoms, alkoxy having 1, 2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;
R4 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R5 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R6 and R7
are independently of one another hydrogen, F or alkyl having 1, 2, or 3 C atoms;
and the pharmaceutically acceptable salts and trifluoroacetates thereof.

### Claim 3 (depends on 1)

A compound of formula I as claimed in claim 1, in which:
A is C or S═O;
n is 0, 1, 2 or 3;
R1 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl or 8-quinolinyl,
where each of these aryl radicals is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 C atoms, OCF3, methylsulfonyl, CF3 and alkyl having 1, 2, 3 or 4 C atoms;
or
R1 is cyclohexyl;
R2 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl or 8-quinolinyl,
where each of these aryl radicals is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of Cl, Br, I, CN, CF3, alkyl having 1, 2, 3 or 4 C atoms;
R3 is CpH2p—R8;
p is 0, 1, 2, 3 or 4;
R8 is CH3, CH2F, CHF2, CF3, cycloalkyl having 3, 4, 5 or 6 C atoms, C≡CH, C≡C—CH3, alkoxy having 1, 2, 3 or 4 C atoms, phenyl or 2-pyridyl,
where phenyl and 2-pyridyl are unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 C atoms and alkoxy having 1, 2, 3 or 4 C atoms;
R4 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R5 is hydrogen or alkyl having 1, 2 or 3 C atoms;
R6 and R7
are independently of one another hydrogen, F or alkyl having 1, 2, or 3 C atoms;
and the pharmaceutically acceptable salts and trifluoroacetates thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or additives.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising an effective amount of at least one compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or additives, and in combination with one or more other pharmacologically active ingredients or pharmaceuticals.

### Claim 6 (depends on 1)

A method for the therapy or prophylaxis of one or more K+ channel-mediated diseases, the method comprising the administration of a K+ channel-blocking effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A method for the therapy or prophylaxis of cardiac arrhythmias which can be abolished by prolonging action potential, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A method for the therapy or prophylaxis of reentry arrhythmias, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A method for the therapy or prophylaxis of supraventricular arrhythmias, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A method for the therapy or prophylaxis of atrial fibrillation or atrial flutter, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A method for the therapy or prophylaxis of respiratory disorders, neurodegenerative disorders or cancers, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A method for the therapy or prophylaxis of sleep-related respiratory disorders, central and obstructive sleep apneas, Cheyne-Stoke's breathing, snoring, impaired central respiratory drive, sudden infant death syndrome, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders following long-term ventilation, respiratory disorders associated with altitude adaptation, acute and chronic pulmonary disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer, lung cancer, colon cancer or prostate cancer, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A method for the therapy or prophylaxis of heart failure and for increasing atrial contractility, the method comprising the administration of a pharmaceutically effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13 wherein the heart failure is diastolic heart failure.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a beta blocker as active ingredients, together with one or more pharmaceutically acceptable carriers or additives.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and an IKs channel blocker as active ingredients, together with one or more pharmaceutically acceptable carriers or additives.
